US Patent 8,231,906: Scope, Claims Breakdown, and US Estradiol Transdermal Patent Landscape
US Drug Patent 8,231,906 is directed to a monolithic transdermal estradiol drug delivery system built around a single polymer matrix layer containing estradiol as the only drug. The claim set narrows on (i) specific coat weights (12.5 or 15 mg/cm²), (ii) a numeric minimum drug loading (>0.156 mg/cm²), and (iii) a numeric minimum estradiol flux (>0.01 mg/cm²/day). Dependent claims further constrain the polymer matrix composition to a defined acrylic/silicone/PVP blend and constrain penetration enhancers (oleyl alcohol and/or dipropylene glycol) plus specific weight ranges and adhesive ratio limits. Method and use claims mirror the structural limits of system claims and add “administer” and “making” steps that track the same quantitative specifications.
Bottom line for freedom-to-operate (FTO): this estate is likely to be claim-narrow but technically strict. Noninfringing designs generally need to move outside at least one of the hard numeric thresholds (coat weight, estradiol loading, flux, active surface area fraction) or materially change the polymer blend composition/penetration enhancer profile recited in dependent claims.
What does US Patent 8,231,906 claim for monolithic estradiol transdermal delivery?
Core invention in Claim 1 (system claim):
- Device type: “monolithic transdermal drug delivery system”
- Architecture: single polymer matrix layer defining an active surface area
- Drug content: estradiol as the only drug in that polymer matrix
- Quantitative constraints:
- coat weight: 12.5 mg/cm² or 15 mg/cm²
- estradiol loading: >0.156 mg/cm²
- estradiol flux: >0.01 mg/cm²/day (based on the active surface area)
Structural meaning for claim scope:
- “Monolithic” is a limitation on the layer count and function: a single matrix layer that both holds drug and provides delivery. Multi-layer systems (for example, separate reservoir and rate-controlling layers) can be outside scope if they do not meet “single polymer matrix layer” as construed.
- “Estradiol as the only drug” excludes matrices containing other pharmacologically active drugs in the polymer matrix. Co-dosed actives elsewhere on the system can still create design risk depending on claim construction of “comprising estradiol as the only drug” (whether it allows non-drug components only).
Quantitative limits are likely to be the main infringement drivers:
In practice, flux and loading thresholds are measurable and become central to both infringement analysis and validity arguments (enablement, definiteness, and written description often focus on the numeric boundaries).
How do dependent claims in US 8,231,906 narrow the polymer matrix composition?
Claim 2: What polymer blend is required?
Claim 2 requires the polymer matrix comprises a blend of:
- an acrylic adhesive
- a silicone adhesive
- soluble PVP (polyvinylpyrrolidone)
This is a compositional limitation layered onto the already constrained architecture and numeric thresholds from Claim 1.
Claim 3: What are the exact weight ranges for acrylic/silicone/PVP and penetration enhancer?
Claim 3 specifies composition on total dry weight of the polymer matrix:
- Acrylic adhesive: 2–25% by weight
- Silicone adhesive: 45–70% by weight
- Soluble PVP: 2–25% by weight
- Penetration enhancer: 5–15% by weight
This claim is a “ratio window” that can be used as a design-around target. Moving any component outside its stated range reduces literal infringement likelihood, assuming the polymer is otherwise within scope.
Claims 4–6: What penetration enhancers are claimed?
The penetration enhancer is limited to:
- Claim 4: oleyl alcohol
- Claim 5: dipropylene glycol
- Claim 6: both oleyl alcohol and dipropylene glycol
If a competitor uses a different enhancer system (for example, menthol, isopropyl myristate, propylene glycol derivatives outside dipropylene glycol, or other enhancers), then the dependent-claim pathway is weakened, though Claim 1 could still be asserted if the independent limitations are met.
Claim 7: What adhesive ratio is required?
Claim 7 constrains acrylic adhesive to silicone adhesive in the acrylic+silicone blend:
- ratio from about 1:2 to about 1:6 (acrylic:silicone), based on total weight of acrylic and silicone adhesives
This adds an additional algebraic constraint that can be mapped to the weight ranges in Claim 3.
What dosage/flux settings are explicitly claimed in US 8,231,906?
The claims include multiple numeric dosing proxies tied to active surface area and flux performance.
Claim 8: What duration options are claimed?
Claim 8 limits therapeutic duration options:
- at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days
This is an “intended delivery over time” limitation. For infringement, the claimed device must be capable of delivering therapeutically effective amounts over those durations consistent with the flux requirement in Claim 1.
Claim 9: What estradiol/day delivery amounts are claimed?
Claim 9 limits to specific daily delivery amounts:
- about 0.025, 0.0375, 0.05, 0.075, or 0.1 mg/day
These are likely the practical embodiments of the flux and loading thresholds in Claim 1, combined with the active surface area selection.
Claim 10: What is the combined active surface area and dose mapping?
Claim 10 adds a structured mapping:
- coat weight: 12.5 mg/cm² or 15 mg/cm²
- active surface area is about 60% of a size selected from:
- 2.5, 3.75, 5.0, 7.5, or 10.0 cm²
- dose/day is about:
- 0.025, 0.0375, 0.05, 0.075, or 0.1 mg/day, “respectively”
This is a classic claim format that ties geometry to dosing. It creates a relatively clean design-around: alter active surface area or the fraction of “about 60%” so that the claimed mapping no longer holds.
How does US 8,231,906 handle administration and method-of-making claims?
Claim 11: What method of administering is claimed?
Claim 11 is essentially the device from Claim 1 packaged as a use/admin step:
- administer to skin or mucosa
- the subject in need thereof
- device is defined by:
- single polymer matrix layer
- active surface area
- estradiol as the only drug
- coat weight 12.5 or 15 mg/cm²
- estradiol loading >0.156 mg/cm²
- flux >0.01 mg/cm²/day
Claim 12: What administration dosing specifics are claimed?
Claim 12 adds Claim 10’s active surface area fraction and dose mapping onto Claim 11.
Claim 13–14: What is claimed in the method of making?
Claim 13 recites manufacturing steps tightly tied to composition and coat weight:
- forming a polymer matrix comprising:
- estradiol as the only drug
- polymer blend including acrylic adhesive, silicone adhesive, soluble PVP
- applying polymer matrix to support layer to form a single polymer matrix layer
- ensuring:
- coat weight 12.5 mg/cm² or 15 mg/cm²
- estradiol loading >0.156 mg/cm²
Claim 14 adds the active surface area “about 60%” constraint.
Practical impact: manufacturing claims are often narrower than infringement on the finished product because they require the specific process steps and target the “how” rather than only the “what.” But if a generic or licensee makes the same monolithic matrix using the same general approach, these claims can become leverage points in litigation.
How strong is the patent estate for broad protection versus narrow, measurable embodiments?
Based on the claim language provided, the estate’s breadth is limited by:
- Single-matrix architecture (“monolithic” and “single polymer matrix layer”).
- Drug identity and exclusivity (“estradiol as the only drug”).
- Hard numeric performance/chemistry thresholds:
- coat weight exactly selected from two values
- estradiol loading above a minimum
- estradiol flux above a minimum
- Dependent composition restrictions:
- acrylic/silicone/PVP blend with numeric weight ranges
- enhancer restriction to oleyl alcohol and/or dipropylene glycol
- adhesive ratio constraint
Overall assessment (from the claims alone): enforcement leverage is strongest against products that are engineered to meet those exact performance targets using the same polymer chemistry stack and monolithic layer structure. If a competitor stays close to the threshold (for example, coat weight 12.5 or 15 mg/cm² is used, but estradiol loading or flux is tuned just under the threshold, or the polymer blend uses a different adhesive polymer family), it can reduce literal coverage, though other theories (doctrine of equivalents) can still be argued.
What design-around paths are most likely to avoid literal infringement?
Design-around analysis keyed to each limitation:
A. Change layer architecture
- Use a multi-layer transdermal structure (separate backing, reservoir/rate-control layers, or non-monolithic designs) to avoid “single polymer matrix layer” limitation.
B. Break the numeric thresholds
- Alter coat weight so it is not 12.5 or 15 mg/cm².
- Adjust estradiol loading to be ≤0.156 mg/cm².
- Tune formulation/processing to achieve flux ≤0.01 mg/cm²/day.
C. Change the polymer chemistry in dependent claims
- Replace the PVP type or polymer entirely (if not “soluble PVP”).
- Replace acrylic adhesive family or silicone adhesive family so composition is outside the stated weight ranges.
- Use penetration enhancers other than oleyl alcohol and/or dipropylene glycol.
D. Break the geometry-dose mapping
- Move active surface area away from the “about 60% of” selected baseline sizes (2.5, 3.75, 5.0, 7.5, 10.0 cm²) so the claimed dose/day mapping no longer aligns.
How does this claim set compare with typical estradiol transdermal patent patterns?
Estradiol transdermal IP commonly spans:
- polymer matrix composition (adhesive systems, drug loading)
- permeation enhancers
- manufacturing processes (casting, coating weights, lamination)
- performance targets (flux, delivery amounts)
- dosing geometry (active surface area, delivery rates)
US 8,231,906’s differentiator is the combination of:
- strict architecture (“monolithic” single polymer matrix layer)
- strict quant targets (coat weight, loading, flux)
- strict chemistry constraints in dependent claims (acrylic+silicone+soluble PVP, enhancer selection, weight ranges, adhesive ratio)
- explicit “active surface area about 60% of” mapping to delivered mg/day values
This is more “specification-driven” than “broad concept” protection, which generally reduces claim coverage breadth but increases defensibility when the accused product is built to hit the same target performance.
What patents, Orange Book listings, and Paragraph IV challenges exist for estradiol transdermal around this patent?
No complete patent landscape can be generated from the information provided. The claims text identifies what this US patent claims, but it does not include the patent assignee, publication/application number, filing date, family members, related US patents, or the FDA product(s) mapped to the claimed dose rates. Without those identifiers, a reliable cross-patent landscape (related continuations, divisionals, and family members) and an Orange Book status view cannot be produced.
Key Takeaways
- US 8,231,906 protects a monolithic estradiol transdermal system built on a single polymer matrix layer with estradiol as the only drug.
- Independent Claim 1 is anchored to three numeric performance/quantity limits: coat weight (12.5 or 15 mg/cm²), estradiol loading (>0.156 mg/cm²), and estradiol flux (>0.01 mg/cm²/day).
- Dependent claims add a narrow polymer chemistry profile: acrylic adhesive + silicone adhesive + soluble PVP, with defined weight ranges, plus penetration enhancer limits to oleyl alcohol and/or dipropylene glycol and an adhesive ratio constraint.
- Administration and method-of-making claims largely track the same quantitative thresholds and composition requirements, making the estate most enforceable against products engineered to meet the same measurable delivery performance and matrix formulation targets.
- The most credible noninfringing routes are to change architecture (multi-layer), move coat weight off the two claimed values, keep loading and/or flux below the stated thresholds, replace enhancer or polymer blend outside the dependent-claim envelopes, or alter active surface area such that the dose mapping no longer matches.
FAQs
- How do coat weight and estradiol flux thresholds typically affect infringement of transdermal matrix patents?
- If a generic uses a different penetration enhancer than oleyl alcohol/dipropylene glycol, can it still infringe Claim 1 of US 8,231,906?
- What is the legal impact of “estradiol as the only drug” when other non-therapeutic actives or excipients are present?
- How can changing active surface area avoid claims that map geometry to mg/day delivery?
- Do manufacturing-process claims (method of making) strengthen litigation leverage even when finished-product composition is engineered around?
References
- US Patent 8,231,906, “Monolithic transdermal drug delivery system for estradiol,” claims text provided in prompt.
